Thrombotic RIsk FActors in AL-goneurodystrophy

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07435207

Acronym

TRIF-AL

Enrollment

120

Registered

2026-02-27

Start date

2026-01-26

Completion date

2027-06-30

Last updated

2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Algoneurodystrophy

Brief summary

The primary objective of the study is to evaluate the prevalence of blood prothrombotic factors in CRPS patients and their role in predicting response to neridronic acid treatment.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Clinical (according to Budapest clinical diagnostic criteria for CRPS) * patients aged 18 years or more

Exclusion criteria

patients unable to give consent \-

Design outcomes

Primary

Measure	Time frame	Description
Pain VAS	1,3 and 6 months after therapy	change in Pain VAS

Countries

Italy

Outcome results